Selecta Biosciences: Q2 Earnings Insights

 

Shares of Selecta Biosciences SELB were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share were up 100.00% over the past year to $0.00, which beat the estimate of ($0.12).

Revenue of $19,663,000 rose by 0.00% year over year, which beat the estimate of $6,240,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 12, 2021

Time: 08:30 AM

ET Webcast URL: https://78449.choruscall.com/dataconf/productusers/selb/mediaframe/40627/indexr.html

Price Action

52-week high: $5.70

52-week low: $1.47

Price action over last quarter: Up 28.19%

Company Overview

Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!